Related to FDA Requests More Data from Existing Trials with Protalix’ Gaucher Disease Drug

• Shire’s Transdermal Patch for ADHD Gets FDA Thumbs Up for Use in Adolescents
  
• FDA Sets Priority Review Schedule for BMS and Otsuka’s sNDA for Sprycel as First-Line CML Therapy
  
• FDA Panel Says Nay to Full Approval of Avastin in Her2-Negative Breast Cancer
  
• NicOx Shares Plummet as FDA Says Osteoarthritis Drug Not Ready for Approval
  
• FDA Green-Lights Thermo Fisher Scientific’s VRE Diagnostic
  
• Abbott Returns U.S. Flutiform Rights to SkyePharma after Negative FDA Feedback
  
• EpiCept’s Stock Slumps as FDA Asks for More Clinical Data on Ceplene
  
• FDA Sanctions Alexion’s RI Production Plant for Commercial Supply of Soliris
  
• Shire Gains EC Nod for Gaucher Disease Treatment
  
• Genentech Receives Refuse to File Letter for T-DM1 in Metastatic Breast Cancer
  
• FDA Okays Novartis’ Hypertension Combination Therapy
  
• Halozyme to Meet with FDA on Re-Introduction of Hylenex
  
• FDA Clears Allergan’s Lumigan 0.01% Eye Drops for Lowering Intraocular Pressure
  
• FDA Gives Abbott a Thumbs-Up for Automated HBV Monitoring Test
  
• Cell Therapeutics to Appeal FDA Decision on Pixantrone NDA
  
• Guilty by Admission: Forest Forfeits $300M for Selling Unapproved Drug
  
• Arena and Eisai’s Obesity Therapy Weighed Down by FDA Panel Vote against Approval
  
• FDA Significantly Restricts Access to GSK’s Antidiabetic Avandia
  
• Allergan Gains FDA Approval for Ozurdex to Treat Noninfectious Posterior Uveitis
  
• FDA Doles Out New Rules on Clinical Trial Safety Data Reporting